Table 2. Summary of Treatment Related Adverse Events		
Adverse Events	**Any grade *n* (%)**	**Grade ≥ 3 *n* (%)**
Overall safety outcomes		
Dose limiting toxicities in stage I	0 (0)	0 (0)
Treatment related adverse events*	39 (65)	7 (12)
Grade 4 or 5 treatment related adverse events	0 (0)	0 (0)
Adverse events leading to dose modification	0 (0)	0 (0)
Adverse events leading to treatment discontinuation	0 (0)	2 (3.3)
Most common adverse events		
>10% of patients		
Anemia	13(22)	3 (5)
Fatigue	8 (13)	1 (2)
Alkaline phosphatase increased	8 (13)	0 (0)
Alanine aminotransferase increased	7 (12)	0 (0)
>5% of patients		
Arthralgia	5 (8)	0 (0)
Rash (maculo-papular)	5 (8)	0 (0)
Aspartate aminotransferase increased	4(7)	1 (2)
Other Grade 3 treatment related adverse events < 5%		
Hypotension	1 (2)	1 (2)
Generalized muscle weakness	1 (2)	1 (2)
Guillane Barre Syndrome	1 (2)	1 (2)

* includes all at least possibly treatment related adverse events